[go: up one dir, main page]

WO2000035431A3 - Treatment of erectile dysfunction in diabetes patients - Google Patents

Treatment of erectile dysfunction in diabetes patients Download PDF

Info

Publication number
WO2000035431A3
WO2000035431A3 PCT/GB1999/004095 GB9904095W WO0035431A3 WO 2000035431 A3 WO2000035431 A3 WO 2000035431A3 GB 9904095 W GB9904095 W GB 9904095W WO 0035431 A3 WO0035431 A3 WO 0035431A3
Authority
WO
WIPO (PCT)
Prior art keywords
erectile dysfunction
treatment
diabetes patients
nitrergic
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/004095
Other languages
French (fr)
Other versions
WO2000035431A2 (en
Inventor
Selim Cellek
Salvador Moncada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Priority to AU16664/00A priority Critical patent/AU1666400A/en
Priority to EP99959520A priority patent/EP1137460A2/en
Publication of WO2000035431A2 publication Critical patent/WO2000035431A2/en
Publication of WO2000035431A3 publication Critical patent/WO2000035431A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Prevention or reduction of nitrergic nerve degeneration in diabetic men can be effected by use of an inhibitor of nitric oxide synthase. Such prevention or reduction of nitrergic nerve degeneration can prevent erectile dysfunction in diabetic man, as such dysfunction is caused by a selective defect in the nitrergic nerves innervating the penis.
PCT/GB1999/004095 1998-12-11 1999-12-06 Treatment of erectile dysfunction in diabetes patients Ceased WO2000035431A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU16664/00A AU1666400A (en) 1998-12-11 1999-12-06 Treatment of erectile dysfunction in diabetes patients
EP99959520A EP1137460A2 (en) 1998-12-11 1999-12-06 Treatment of erectile dysfunction in diabetes patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9827393.1 1998-12-11
GBGB9827393.1A GB9827393D0 (en) 1998-12-11 1998-12-11 Treatment of erectile dysfunction in diabetes patients

Publications (2)

Publication Number Publication Date
WO2000035431A2 WO2000035431A2 (en) 2000-06-22
WO2000035431A3 true WO2000035431A3 (en) 2000-11-09

Family

ID=10844117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/004095 Ceased WO2000035431A2 (en) 1998-12-11 1999-12-06 Treatment of erectile dysfunction in diabetes patients

Country Status (4)

Country Link
EP (1) EP1137460A2 (en)
AU (1) AU1666400A (en)
GB (1) GB9827393D0 (en)
WO (1) WO2000035431A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
FR2753098A1 (en) * 1996-09-06 1998-03-13 Sod Conseils Rech Applic PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE NO SYNTHASE INHIBITOR AND AT LEAST ONE TRAP FOR REACTIVE OXYGEN FORMS
WO1998013037A1 (en) * 1996-09-25 1998-04-02 The Regents Of The University Of California Methods of using agmatine to reduce intracellular polyamine levels and to inhibit inducible nitric oxide synthase
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
WO1998042361A1 (en) * 1997-03-26 1998-10-01 Spencer E Martin Human erectile dysfunction and methods of treatment
WO1998051260A2 (en) * 1997-05-14 1998-11-19 Redox, Inc. Use of d-arginine and/or l-arginine to protect the amino groups of biological substances from damage, inactivation, or modification by toxic carbonyls and/or dicarbonyls
WO1999057114A1 (en) * 1998-05-04 1999-11-11 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
FR2753098A1 (en) * 1996-09-06 1998-03-13 Sod Conseils Rech Applic PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE NO SYNTHASE INHIBITOR AND AT LEAST ONE TRAP FOR REACTIVE OXYGEN FORMS
WO1998013037A1 (en) * 1996-09-25 1998-04-02 The Regents Of The University Of California Methods of using agmatine to reduce intracellular polyamine levels and to inhibit inducible nitric oxide synthase
WO1998042361A1 (en) * 1997-03-26 1998-10-01 Spencer E Martin Human erectile dysfunction and methods of treatment
WO1998051260A2 (en) * 1997-05-14 1998-11-19 Redox, Inc. Use of d-arginine and/or l-arginine to protect the amino groups of biological substances from damage, inactivation, or modification by toxic carbonyls and/or dicarbonyls
WO1999057114A1 (en) * 1998-05-04 1999-11-11 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CELLEK S; RODRIGO J; LOBOS E; FERNANDEZ P; SERRANO J AND MONCADA S: "Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon", BRITISH JOURNAL OF PHARMACOLOGY, vol. 128, no. 8, December 1999 (1999-12-01), pages 1804 - 1812, XP002141458 *
FRATI-MUNARI A C ET AL: "[Treatment of diabetic neuropathy]. Tratamiento de la neuropatia diabetica.", GACETA MEDICA DE MEXICO, (1998 JAN-FEB) 134 (1) 85-92. REF: 51, XP000920623 *
KOUR NAM-WEE; YAJIMA MICHITAKA; LEE SHANG-SEN; LUE TOM F; TANAGHO EMIL A: "Aminoguanidine reverses the impairment of cavernous nerve induced intracavernosal pressure response in streptozotocin diabetic rats.", JOURNAL OF UROLOGY, vol. 151, no. 5 SUPPL., 1994, pages 429A, XP000920621 *
R. BERKOW: "The Merck Manual of Diagnosis and Therapy, Fifteenth Edition", MERCK SHARP & DOHME RESEARCH LABORATORIES, NEW YORK, XP002141459 *
SEFTEL, A.D.; VAZIRI, N.D.; NI, Z.; RAZMJOUEI, K.; FOGARTY J. ET AL.: "Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS.", UROLOGY, vol. 50, no. 6, December 1997 (1997-12-01), pages 1016 - 1026, XP000920679 *
TESFAYE S.: "Diabetic neuropathy: Current treatment and potential therapeutic approaches.", DIABETES, NUTRITION AND METABOLISM - CLINICAL AND EXPERIMENTAL, (1994) 7/ (375-379)., XP000920809 *

Also Published As

Publication number Publication date
WO2000035431A2 (en) 2000-06-22
AU1666400A (en) 2000-07-03
GB9827393D0 (en) 1999-02-03
EP1137460A2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
WO2006029257A3 (en) Neurostimulation methods and systems
WO2005100392A3 (en) Treatment of neuropathic pain with zinc finger proteins
WO2002015722A3 (en) Treatment of helicobacter with isothiocyanates
Morrow et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life
WO2002030508A3 (en) Nerve cuff electrode
AU2295895A (en) Dosage forms and method for ameliorating male erectile dysfunction
GB0300789D0 (en) Stimulation method for the sphenopalatine ganglia,sphenopalatine nerve,or vidian nerve for treatment of medical conditions
WO2006031980A3 (en) Treatment for cancer-related fatigue
WO2000043395A8 (en) Substituted porphyrins
WO2006015086A3 (en) Methods of affecting hypothalamic-related conditions
WO2003059942A3 (en) Peptides and peptidomimetics having anti-proliferative activity and their use
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
UA86345C2 (en) Normal;heading 1;heading 2;USE OF OSTEOPROTEGERIN FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS
WO2000038666A3 (en) A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
WO2002053106A3 (en) Autoantigen composition
GB0308952D0 (en) Method
WO2000074710A3 (en) Methods for treating diabetes
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
WO2004098527A3 (en) Methods of treating neuralgic pain
WO2000035431A3 (en) Treatment of erectile dysfunction in diabetes patients
CA2430467A1 (en) Means and method for treating an intimal dissection after stent implantation
WO2002094247A3 (en) Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2003020257A3 (en) USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16664

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999959520

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09857601

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999959520

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999959520

Country of ref document: EP